Edu Hortelano (@eduhor82) header
Edu Hortelano (@eduhor82) profile picture

Radiation Oncologist,MD. Álava University Hospital,Basque Country(Spain)

Vitoria-Gasteiz, España
Joined June 2015
Photo by Edu Hortelano (@eduhor82)Photo by Edu Hortelano (@eduhor82)Photo by Edu Hortelano (@eduhor82)Photo by Edu Hortelano (@eduhor82)Photo by Edu Hortelano (@eduhor82)Photo by Edu Hortelano (@eduhor82)Photo by Edu Hortelano (@eduhor82)Photo by Edu Hortelano (@eduhor82)Photo by Edu Hortelano (@eduhor82)Photo by Edu Hortelano (@eduhor82)
Edu Hortelano retweeted
12 señales de que te estás volviendo más atractivo (y no te das cuenta):
11
64
1,766
793,241
Edu Hortelano retweeted
👶“Se podrá ser madre a los 90 años” 😳Sobre cómo será el mundo en un futuro no muy lejano charlan el neurocirujano y médico de longevidad, José Poveda y Alberto Herrera, en @herreraencope🎧
27
13
4
205
23,160
Edu Hortelano retweeted
100+ AI Tools to replace your tedious work: 1. Research - ChatGPT - YouChat - Abacus - Perplexity - Copilot - Gemini 2. Image - Higgsfield AI Soul - GPT-4o - Midjourney - Grok 3. Productivity - Gamma - Grok 3 - Perplexity AI - Gemini 2.5 Flash 4. Writing - Jasper - Jenny AI - Textblaze - Quillbot 5. Video - Klap - Kling - InVideo - HeyGen - Runway 6. Meeting - Tldv - Otter - Noty AI - Fireflies 7. SEO - VidIQ - Seona AI - BlogSEO - Keywrds ai - Outrank AI 8. Presentation - Decktopus - Slides AI - Gamma AI - Designs AI - Beautiful AI 9. Design - Canva - Flair AI - Designify - Clipdrop - Autodraw - Magician design 10. Audio - Lovo ai - Eleven labs - Songburst AI - Adobe Podcast 11. Marketing - Pencil - Ai-Ads - AdCopy - Simplified - AdCreative 12. Startup - Tome - Ideas AI - Namelix - Pitchgrade - Validator AI 13. Social media management - Tapilo - Typefully - Hypefury - TweetHunter Follow @sripathiteja4 for more.
79
143
3
475
169,935
Preparando los pasos prohibidos para Nochevieja....
22
59
7
290
25,788
CHAARTED 10-Year Analysis PSA nadir <0.2 at 6 months predicts better long-term survival in metastatic hormone-sensitive prostate cancer (mHSPC), independent of treatment arm! Could PSA nadir be a future de-escalation marker? @ChrisSweens1 #ProstateCancer #Oncology #CancerResearch #PrecisionMedicine @asco @oncoalert @MikeSerzanMD @drenriquegrande @crisbergerot @reginabarcar @DRBakaloudiMD @abvilima @ReneeSaliby @yekeduz_emre @neerajaiims @DrChoueiri @montypal @PGrivasMDPhD @CParkMD @OncLive @amerseburger
2
38
97
5,903
Another great metastatic prostate cancer "landscape" figure from @aaparicioMD during her aggressive variant prostate cancer talk at #ESMO25 Approved, and "likely to be approved"/new data (bottom), treatment options @urotoday
Drug Approvals in 🇺🇸 for Prostate Cancer (2010-2025) Go ahead and bookmark this beauty from @PBarataMD @urotoday #ESMO25
74
1
232
31,243
What were the results of the Postoperative Radiation Therapy in Endometrial Carcinoma (PORTEC) 3 trial? droracle.ai/articles/107827/…
65
Edu Hortelano retweeted
🚨 The 2024 FROGG Guidelines for Post-Prostatectomy Radiation Therapy (PPRT) are here, bringing groundbreaking updates backed the by the latest evidence❗️@OncoAlert 🧵1/7
2
65
4
147
18,186
Edu Hortelano retweeted
SRS 10+ brain mets week 1/4 Are survival outcomes similar to patients w/2-9 brain mets? YES, according to this study doi.org/10.3171/2014.8.GKS14…
1
16
1
40
3,935
Ten Practice Changes That I Will Make After Attending ASCO 2024 | PracticeUpdate practiceupdate.com/content/t…
66
Replying to @ASTRO_org
@ASTRO_org Updates Rectal Cancer Radiation Therapy Clinical Guideline 🔗 bit.ly/4iIB24X “This updated guideline incorporates new, practice-changing data that expand treatment options for people with rectal cancer." #RadOncNews #RadOnc #ASTRO
2
5
506
🌟 Looking ahead: Prostate Cancer (PCa) management in 2025 Moderator: Amit Bahl | Nuclear Medicine Insights by @karolien_goffin #PROSCA24 @OncoAlert @mirrorsmed 🔹 PSMA-based Radioligand Therapy (RLT) 🧬 PSMAfore: 12.0 vs 5.6 months (PFS benefit) 🧬 SPLASH: 9.5 vs 6.0 months (PFS benefit) 🧬 ECLIPSE: Promising outcomes! 🌟 🔹 Future of RLT 📡 Integrates isotopes, PET imaging, & immunotherapy 🧪 Exploring alpha therapy: Actinium-225 shows remarkable efficacy! 🔹 Innovative Trials in 2025 🌍 Expanding RLT applications globally 🛠️ Enhancing targeted treatments with PSMA-based approaches 🔹 Beyond Beta 🅱️ Lu-PSMA achieves great outcomes 🔬 Alpha therapies (Actinium-225) show groundbreaking potential 💪 🔹 Radiation Oncology Evolution 🌟 From clinical trials to future standards 🌐 Revolutionizing Nuclear Medicine & PCa Treatment! @UrsulaVogl @PGrivasMDPhD @achoud72 @ZilliThomas @fabioturco92 @yekeduz_emre @niklas_kluemper @nachoduranm @schmidingerRCC @DrDabestani @bavilima @PignotG @lisapic @DrYukselUrun @b_szabados @Silke_Gillessen @APCCC_Lugano #PSMA #NuclearMedicine #ProstateCancer #PrecisionOncology #RadioligandTherapy #PROSCA24 💡
2
13
1
30
4,706
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 sciencedirect.com/science/ar… NOW ON FINAL SESSION of #PROSCA24 The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking. The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting. The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer. Our Thanks to all authors: @Silke_Gillessen @fabioturco92 @Prof_IanD @drjefstathiou Karim Fizazi @Prof_Nick_James Neal Shore Eric Small Matthew Smith @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims Emmanuel S. Antonarakis Ana Aparicio Andrew J. Armstrong Diogo Assed Bastos Gerhardt Attard Karol Axcrona Mouna Ayadi Himisha Beltran @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti Muhammad Bulbul Consuelo Buttigliero Orazio Caffo @cdanicas @Ecastromarcos Heather H. Cheng Kim N. Chi Caroline S. Clarke Noel Clarke Johann S. de Bono @mdesantis234 @nachoduranm @EfstathiouEleni Onyeanunam N. Ekeke Tamer I.H. El Nahas @drlouiseemmett @stefanofanti4 Omolara A. Fatiregun Felix Y. Feng Peter C.C. Fong @fontev1 @Nicola_Fossati Daniel J. George @marty_gleave Gwenaelle Gravis Susan Halabi Daniel Heinrich @ProfKHerrmann @DrMHofman Thomas A. Hope Lisa G. Horvath Maha H.A. Hussain @BarbaraJereczek Robert J. Jones Anthony M. Joshua @ravikanesvaran Daniel Keizman @FacsRaja Gero Kramer @LoebStacy Brandon A. Mahal Fernando C. Maluf 75 76, @quimmateo David Matheson 78, Mika P. Matikainen 79, Ray McDermott 80, @DrRanaMcKay Niven Mehra 82, @amerseburger @CaPsurvivorship Michael J. Morris 85, Hind Mrabti 86, Deborah Mukherji @declangmurphy Vedang Murthy Shingai B.A. Mutambirwa @DrPaulNguyen @WilliamOhMD @piet_ost Joe M. O’Sullivan Anwar R. Padhani Chris Parker Darren M.C. Poon Colin C. Pritchard Danny M Rabah Dana Rathkopf Robert E. Reiter Raphaele Renard-Penna Charles J. Ryan Fred Saad Juan Pablo Sade Shahneen Sandhu Oliver A. Sartor Edward Schaeffer Howard I. Scher Nima Sharifi Iwona A. Skoneczna Howard R. Soule @DrSpratticus Sandy Srinivas @cnsternberg Hiroyoshi Suzuki Mary-Ellen Taplin Camilla Thellenberg-Karlsson Derya Tilki Levent N. Türkeri Hiroji Uemura @DrYukselUrun Claire L. Vale Neha Vapiwala Jochen Walz Kosj Yamoah Dingwei Ye Evan Y. Yu Almudena Zapatero @AOmlin
8
95
7
182
30,551
Edu Hortelano retweeted
Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment, published in @TheLancet. 👉 Read it before your patients: bit.ly/3Tr8WzY #ESTRONewsletter #breastcancer
4
5
882
Edu Hortelano retweeted
🌍 ESTRO at ASTRO! ESTRO President Matthias Guckenberger @Mat_Guc is presenting highlights from the best science of #ESTRO24 at the "Cancer Breakthroughs" session at #ASTRO24. 🚀✨ #CancerResearch #GlobalCollaboration
5
32
1,950
Edu Hortelano retweeted
Doublet chemotherapy, triplet chemotherapy, or doublet chemoT combined with RT as neoadjuvant treatment for locally advanced #oesophagealcancer: a randomised, controlled, open-label, phase 3 trial, published in @TheLancet. 👉 Read it before your patients: bit.ly/3XRD8WD
4
4
958
Edu Hortelano retweeted
Randomised, double-blind, phase 3 clinical trial for newly diagnosed, high-risk, locally advanced cervical cancer, published in @TheLancet. 👉 Read it before your patients: bit.ly/46Ywx0s #ESTRONewsletter
3
2
583
Edu Hortelano retweeted
Probably the best current review on PSMA expression ... congrats to @mishabeltran @mkbakht nature.com/articles/s41585-0…
Check out our new review in @NatRevUrol on biologic determinants of PSMA expression, regulation, and heterogeneity in prostate cancer led by @mkbakht @DanaFarber_GU @PCF_Science Link to paper: rdcu.be/dM7GF nature.com/articles/s41585-0…
3
60
1
181
28,876